araag2/HINT huggingface dataset:
Clinical trial NCT02130622 (phase 2, status: terminated)
Conditions: diabetic gastroparesis
ICD codes: K31.84
Drugs: promethazine, sugar pill
SMILES: CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 18-65 years of age

          -  clinical diagnosis of diabetic gastroparesis.

          -  EGD without evidence of gastric outlet obstruction within the past five years

          -  gastric emptying scintigraphy test demonstrating >10% solid food retention at 4 hours
             within the past three years.

        Exclusion Criteria:

          -  the inability or unwillingness to provide informed consent

          -  currently pregnant or breast feeding

          -  prior placement of a gastric stimulator

          -  pyloric botulinum toxin injection within the past 12 months

          -  prior gastric surgery

          -  history of a connective tissue disorder

          -  use of narcotic medication within the past four weeks

          -  hemoglobin A1C >12 mg/dL within the past 3 months

          -  current or recent (within past 4 weeks) use of promethazine, metoclopramide or
             domperidone

          -  hypersensitivity or prior adverse reaction to promethazine

          -  concomitant use of phenothiazines (i.e. prochlorperazine, chlorpromazine) or other
             agents likely to increase extrapyramidal reactions

          -  concomitant use of tiotropium or ipratropium

          -  narrow angle glaucoma

          -  urinary retention

          -  Parkinson's disease

          -  significant psychiatric disease

          -  history of seizure.
Clinical trial NCT02131662 (phase 2, status: completed)
Conditions: leiomyoma
ICD codes: D25.0, D25.1, D25.2, D25.9
Drugs: bay1002670, bay1002670, bay1002670, bay1002670, placebo
SMILES: C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F, C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F, C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F, C[C@]12C[C@H](C3=CC=C(C=C3)S(C)(=O)=O)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at
             screening with at least 1 fibroid with largest diameter 3.0 cm

          -  18 to 50 years of age at the time of screening

          -  Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following
             the screening visit

          -  Normal or clinically insignificant cervical smear not requiring further follow-up

          -  An endometrial biopsy performed at the screening visit 1 (Visit 1), without
             significant histological disorder such as endometrial hyperplasia or other significant
             endometrial pathology

          -  Use of a non-hormonal barrier method of contraception starting at the bleeding episode
             following the screening visit 1 (Visit 1) until the end of the study

          -  Good general health (except for findings related to uterine fibroids)

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Uterine fibroid with largest diameter >10.0 cm

          -  Hypersensitivity to any ingredient of the study drug

          -  Laboratory values outside inclusion range before randomization and considered as
             clinically relevant

          -  Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion
             (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug
Clinical trial NCT02133001 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: esketamine, placebo
SMILES: CNC1(CCCCC1=O)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must meet Diagnostic and Statistical Manual of Mental Disorders, fourth
             edition (DSM-IV) diagnostic criteria for major depressive disorder

          -  Participants must have current suicidal ideation with intent

          -  In the Investigator's opinion, participant must be in need of acute psychiatric
             hospitalization due to imminent risk of suicide

          -  Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of
             greater than or equal to (>=) 22 predose on Day 1

          -  As part of standard of care treatment, participant agrees to be hospitalized
             voluntarily for a recommended period of 5 days after randomization (that is, through
             Day 5), and take prescribed non-investigational antidepressant therapy(ies) for at
             least the duration of the double-blind treatment phase (Day 25)

        Exclusion Criteria:

          -  Participant has a current clinical diagnosis of bipolar or related disorders,
             intellectual disability, or cluster b personality disorder (example, borderline
             personality disorder, antisocial personality disorder, histrionic personality
             disorder, and narcissistic personality disorder)

          -  Participant meets DSM-IV criteria for borderline personality disorder, based on
             clinical interview

          -  Participant has a current or prior diagnosis of a psychotic disorder, major depressive
             disorder (MDD) with psychosis, or obsessive compulsive disorder

          -  Participant with a history or current signs and symptoms of liver or renal
             insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine,
             neurologic, hematologic, rheumatologic, or metabolic disturbances

          -  Participant has uncontrolled hypertension (systolic blood pressure greater than [>]
             160 millimeter of mercury [mmHg] or diastolic blood pressure > 90 mmHg) despite diet,
             exercise or a stable dose of an allowed anti-hypertensive treatment at Screening; or
             any past history of hypertensive crisis
Clinical trial NCT02134106 (phase 2/phase 3, status: withdrawn)
Conditions: bacteremia, healthcare-associated pneumonia, ventilator-associated pneumonia
ICD codes: J95.851
Drugs: polymyxin b, polymyxin b + doripenem
SMILES: [H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
Reason stopped: 
    the target cannot be achieved within timeline due to delay of ethics approval
  
Eligibility criteria:

        Inclusion Criteria:

          -  Monomicrobial XDR-GNB bacteremia.

          -  Monomicrobial XDR-GNB ventilator-associated pneumonia OR healthcare-associated
             pneumonia.

        Exclusion Criteria (will be excluded if subjects meet one or more of the following
        criteria):

          -  Allergy to any of the study medications.

          -  For female patients, the patients is pregnant.

          -  Unable to provide consent and have no legally authorized representatives.

          -  Currently enrolled in another trial.

          -  >48 hours after XDR-GNB confirmation by the microbiology laboratory.

          -  Palliative care or with less than 24 hours of life expectancy, as discussed with their
             primary physicians.

          -  Co-infection with other aerobic Gram-negative bacteria.

          -  Severe renal impairment (creatinine clearance <30 milliliters (mL)/min).

               -  Concurrent infection not involving the lungs or bloodstream is not an exclusion
                  criterion for the study.
Clinical trial NCT02137083 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, fulvestrant
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal female between 18 and 70 years old

          -  ECOG performance status of ≤ 1

          -  Life expectancy more than 3 months

          -  Histologically confirmed metastatic breast cancer

          -  ER and&or PR pqositive, HER2-negative

          -  Disease progression during adjuvant or first-line endocrine therapy, or endocrine
             naive but unsuitable for endocrine therapy alone

          -  No pretreated chemotherapy for metastatic disease

          -  Have at least one target lesion according to RECIST 1.1

          -  No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4
             weeks before enrollment

          -  Hemoglobin ≥ 90 g/L, Absolute Neutrophil Count ≥ 1.5×10^9/L, Platelet Count ≥
             75×10^9/L, Serum Bilirubin ≤ 1.5×ULN, ALT and AST ≤ 1.5×ULN, Serum Creatinine ≤ 1×ULN,
             Endogenous Creatinine Clearance>50ml/min

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Evidence of CNS metastasis

          -  Seriously uncontrolled infection

          -  History of another malignancies except cured basal cell carcinoma of skin and
             carcinoma in-situ of uterine cervix

          -  Pretreated with Fulvestrant

          -  Pretreated with two or more lines of endocrine therapy
Clinical trial NCT02138253 (phase 2, status: completed)
Conditions: liver fibrosis, hepatic fibrosis, liver cirrhosis, hepatic cirrhosis
ICD codes: K71.7, K70.2, K74.01, K74.02, K74.2, K74.00, K74.60, K74.69, P78.81, K71.7, K70.30, K70.31, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30
Drugs: idn-6556, placebo
SMILES: C[C@H](NC(=O)C(=O)NC1=CC=CC=C1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects of minimum adult legal age (according to local laws for
             signing the informed consent document), able to provide written informed consent, and
             able to understand and willing to comply with the requirements of the study

          -  History of orthotopic liver transplantation for HCV-induced liver disease

          -  Diagnosis of HCV infection (HCV-RNA detectable in serum) and liver fibrosis and/or
             incomplete cirrhosis status post liver transplantation, and achieved a sustained
             virologic response (SVR) with anti-viral HCV treatment within 18 months of Day 1

          -  Liver fibrosis on liver histology as read by central histopathologist of Ishak F2 to
             F6 within three months of Day 1 (Up to 15 subjects with an Ishak score of F6 can be
             enrolled)

          -  Willingness to utilize two reliable forms of contraception (for both males and females
             of childbearing potential) from Screening to one month after the last dose of study
             drug

        Exclusion Criteria:

          -  Known infection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV)

          -  History of renal transplant and/or severe renal impairment defined as eGFR (estimated
             glomerular filtration rate) of less than 30 mL/min/1.73 m2

          -  Evidence of tumor burden >Milan criteria, or evidence of micro- or macrovascular
             invasion in explanted liver

          -  Hepatocellular carcinoma (HCC) at entry into the study

          -  Concurrent sirolimus (rapamycin) use

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of > 480 milliseconds (msec)

          -  Subjects with diagnosed or suspected systemic lupus erythematosus (SLE) and/or
             rheumatoid arthritis (RA)

          -  If female: known pregnancy, positive urine or serum pregnancy test, or
             lactating/breastfeeding
Clinical trial NCT02139943 (phase 2, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: canagliflozin 100 mg, canagliflozin 300 mg, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have type 1 diabetes mellitus (T1DM) for at least 1 year

          -  Must have have inadequate glycemic control (as defined by glycosylated hemoglobin
             level of >= 7.0% to <= 9.0%) on basal plus bolus insulin at screening

          -  Must have body mass index 21 to 35 kg/m2 inclusive

          -  Must be on a total daily dose of insulin >= 0.6 IU/kg at screening

          -  Must be on a stable insulin regimen for at least 8 weeks prior to screening

        Exclusion Criteria:

          -  History of T2DM, pancreas or β-cell transplantation, or diabetes secondary to
             pancreatitis or pancreatectomy

          -  Severe hypoglycemia (defined as an event required assistance from another person, or
             which resulted in seizure or loss of consciousness) within 6 months prior to study
             start

          -  Diabetic ketoacidosis within 6 months prior to study start

          -  History of hereditary glucose-galactose malabsorption or primary renal glycosuria

          -  An ongoing, inadequately controlled thyroid disorder
Clinical trial NCT02141035 (phase 2/phase 3, status: completed)
Conditions: carpal tunnel syndrome, compression neuropathy
ICD codes: G56.00, G56.01, G56.02, G56.03
Drugs: acetyl-l-carnitine, placebo
SMILES: CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be recruited from the University of Alberta Hospital referred for CTS.
             Inclusion criteria will include adult patients (over age 18) with at least one of the
             following symptoms:

               1. numbness and parenthesis in the median nerve distribution;

               2. Precipitation of those symptoms by repetitive motions that are relieved by
                  rubbing and or shaking the hands;

               3. Nocturnal awakening by those sensory symptoms, or

               4. Weakness of thumb abduction and thenar atrophy.

        Exclusion Criteria:

          1. Motor unit loss in the median nerve less than 2 SD below the mean for the age as
             determined by nerve conduction studies.

          2. The presence of other neurologic conditions

          3. Previous carpal tunnel release surgery

          4. Cognitive impairment that renders the patient unable to provide informed consent;

          5. Pregnancy
Clinical trial NCT02143843 (phase 2, status: completed)
Conditions: primary open-angle glaucoma, ocular hypertension
ICD codes: H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Completed FSV5-002 study.

          2. Written informed consent prior to any study procedure.

          3. Willingness to comply with the visit schedule.

        Exclusion Criteria:

          1. Participation in an investigational drug or device study other than FSV5-002 within
             the past 6 months or anticipated participation during the study period.

          2. Subjects who will require contact lens use during the study period.

          3. Any condition or situation (such as uncontrolled systemic disease) that, in the
             Investigator's opinion, might confound the results of the study, may put the subject
             at significant risk or might interfere with the subject's ability to participate in
             the study.
Clinical trial NCT02145988 (phase 2/phase 3, status: terminated)
Conditions: diabetes, peripheral arterial disease
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: dlbs1033, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment rate is unexpectedly too low (insufficient number of eligible patients).
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent before any trial related activities.

          -  Male or female subjects of 40 - 65 years of age.

          -  Diagnosis of diabetes mellitus defined as HbA1c level of ≥ 6.5% (for newly diagnosed
             diabetes) or based on medical history.

          -  Presence of peripheral arterial disease with resting ankle-brachial index (ABI) of
             0.41-0.90 inclusive

        Exclusion Criteria:

          -  Females of childbearing potential: pregnancy, breast-feeding, and the intention of
             becoming pregnant.

          -  Recent stroke attack, myocardial infarction/unstable angina/acute coronary syndrome,
             coronary artery bypass surgery (CABG) or percutaneous transluminal coronary
             angioplasty (PTCA)/stent within 3 (three) months prior to screening.

          -  Impaired liver function: serum ALT > 2.5 times upper limit of normal.

          -  Impaired renal function: serum creatinine ≥ 1.5 times upper limit of normal.

          -  Concomitant use of other antithrombosis drugs or any antiplatelets other than the
             study medication.

          -  Subjects with concurrent herbal (alternative) medicines or food supplements

          -  Subjects with any other disease state, including chronic or acute systemic infections,
             uncontrolled illnesses or other chronic diseases, which judged by the investigator,
             could interfere with trial participation or trial evaluation.

          -  Subjects with high risk of bleeding:

          -  Subjects with prior experience with DLBS1033 or other oral lumbrokinase products.

          -  Subjects with known or suspected allergy to any of study medications used in the
             study, including other lumbrokinase products.

          -  Subjects with known or suspected allergy or resistant to aspirin.
Clinical trial NCT02147067 (phase 2, status: completed)
Conditions: microvascular angina
ICD codes: H35.09
Drugs: ranolazine, placebo
SMILES: COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC2=C(C)C=CC=C2C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of typical angina or effort-induced anginal symptoms and are currently
             experiencing angina at least once per week

          -  Abnormal stress ECG, exercise stress imaging, or pharmacological stress imaging

          -  Non-obstructive coronary artery disease as defined by lesion stenosis ≤ 50% in any
             artery as visualized by diagnostic angiography

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Active Myocardial Infarction

          -  History of coronary artery bypass grafting

          -  Diagnosis of other specific cardiac disease such as severe valvular heart disease,
             cardiomyopathy, or variant angina

          -  Left Ventricular Ejection Fraction (LVEF) < 30%

          -  Known renal insufficiency (CrCl < 30 mL/min) or on dialysis

          -  Contraindications to the use of Ranolazine
Clinical trial NCT02147587 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tofacitinib, placebo
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have moderate to severe rheumatoid arthritis inadequately controlled by
             methotrexate as defined by the American College of Rheumatology (ACR) classification
             criteria for Rheumatoid arthritis, painful and swollen joint counts and C-reactive
             protein (CRP).

          -  Screening CRP >3 mg/L or CDAI score > 10 at screening or at baseline before
             vaccination.

          -  Subjects must have active disease at screening and baseline.

          -  Must be at least 50 years of age or older.

        Exclusion Criteria:

          -  History of receiving any varicella-zoster virus vaccine

          -  Receipt of any vaccines within 6 weeks of first dose of study treatment.

          -  Subjects with current infections or history of infections.

          -  History of recurrent (more than one episode) of herpes zoster or disseminated (a
             single episode) of herpes zoster or disseminated (a single episode) of herpes simplex.